Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 31;7(3):279-284.
doi: 10.3233/BLC-210013. eCollection 2021.

Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy

Leslie K Ballas  1 , Andrzej Niemierko  2 , Kimberley S Mak  3 , Michael Drumm  4 , Jason A Efstathiou  2
Affiliations

Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy

Leslie K Ballas et al. Bladder Cancer. .

Abstract

Purpose: Sex-specific differences exist in muscle invasive bladder cancer (MIBC): men have a higher incidence; women present with more advanced disease; and surgical options differ between men and women. Health related quality of life (HRQoL) for male versus female patients with MIBC is not well understood and limited data exists in patients who undergo bladder preservation with trimodality therapy (TMT). The purpose of this study was to compare long-term HRQoL between men and women who have undergone TMT.

Methods and materials: This was a secondary analysis of a prior study that reported long-term HRQoL differences for patients who underwent TMT. We analyzed patient reported HRQoL data to assess differences in HRQoL between men and women.

Results: Of the 64/74 (86%) TMT patients that completed questionnaires, 14 (22%) were women. Median age at diagnosis was 60 years for women and 66 years for men (p = 0.007). From six HRQoL instruments, there were two responses with a statistically significant difference between women and men -incidence of diarrhea and degree of sexual activity. Fifty percent of women compared to 86%of men reported no diarrhea (p = 0.02). A greater percentage of women reported some degree of sexual activity in the 4 weeks prior to questionnaire completion (p = 0.04), and sexual interest following TMT declined significantly with age in men, but not in women.

Conclusions: In general, men and women report very good long-term HRQoL following TMT. There were, however, some differences between the sexes. Understanding this difference, especially related to sexual function, will allow more informed decision making by patients when choosing between treatment modalities.

Keywords: Bladder cancer; MIBC; Trimodality therapy; bladder preservation; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Leslie Ballas: no conflicts of interest to declare. Andrzej Niemierko: no conflicts of interest to declare. Kimberley Mak: no conflicts of interest to declare. Michael Drumm: no conflicts of interest to declare. Jason Efstathiou: personal fees from Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Taris Biomedical, Janssen, Bayer Healthcare, and Roivant Pharma, Myovant Sciences and Merck.

Figures

Fig. 1
Fig. 1
Probability of being interested in sex as a function of age (dashed lines are 95%confidence intervals) for women and men following TMT.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Society AC. Key statistics for bladder cancer. Accessed April 23, 2020. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
    1. Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer. 2014;120(4):555–61. doi: 10.1002/cncr.28416 - DOI - PMC - PubMed
    1. Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498–502; discussion 502-3. doi: 10.1016/j.urology.2008.01.086 - DOI - PubMed
    1. Hollenbeck BK, Dunn RL, Ye Z, et al.. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22):5235–42. doi: 10.1002/cncr.25310 - DOI - PubMed
    1. Witjes JA, Bruins HM, Cathomas R, et al.. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the Guidelines. Eur Urol. 2021;79(1):82–104. doi: 10.1016/j.eururo.2020.03.055 - DOI - PubMed

LinkOut - more resources